To date, several clinical investigations are assessing the safety and antitumor efficacy of CD19/CD20- or CD19/CD22-redirected CAR-Ts for the treatment of individuals with blood-based cancers (NCT03233854, NCT03019055, and NCT03196830). This evidence concerns the gene CD22 and cancer.